01 November 2023
01 November 2023
The controlled, randomised trial will evaluate the safety and efficacy of Radspherin.
Swiss company iOnctura has been granted an investigational new drug application for roginolisib by the FDA, with plans to launch a new Phase I trial.
The company has streamlined the trial protocol designs for the two supplemental trials for Viaskin Peanut following a Type C meeting with the FDA.
As new data from the Phase I part is expected, Aulos will focus on metastatic tumour patients at a later line of treatment in Phase II.
The study intends to demonstrate the immunologic non-inferiority and superiority of the PIKA vaccine against a control vaccine.
Preclinical data showed that BBT-207 demonstrated activity against treatment-emergent complex EGFR mutations.
The company anticipates enrolling 18 subjects across six study centres in China.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
